June 22, 2023 | Advocacy, Funding, Media, Progressive
Multiple Sclerosis New Zealand (MSNZ) is delighted to share that Pharmac have commenced consultation to fund Ocrelizumab for Primary Progressive MS. Currently, those with PPMS have no access to any disease modifying therapies. Ocrelizumab has been proven in trials to […]